| Page 118 | Kisaco Research

Partnerships can transform the trajectory of a health-tech startup. Johanna Majamaa, CEO of GekkoVet discusses how working with Royal Canin enabled the company to validate its platform across 100 clinics, demonstrate real-world impact, and lay the groundwork for expansion into new markets and universities.

Milestone - Collaboration
Technology
Partnerships
Companion
Veterinary

Author:

Johanna Majamaa

Chief Executive Officer
Gekko Vet Oy

Johanna Majamaa

Chief Executive Officer
Gekko Vet Oy

Securing the right exit is critical to ensuring innovation achieves full market potential. Louise Grubb, Managing Director of TriviumVet, shares how the company balanced growth milestones, resisted low valuations, and leveraged regulatory success to secure the right partner at the right time to achieve sustainable scale post-acquisition.

Milestone - Acquisition
Companion
Feline
Canine
Cardiovascular
Renal
Pain
Gastro
Acquisition
Exit

Author:

Louise Grubb

CEO & Co-Founder
TriviumVet

Louise Grubb

CEO & Co-Founder
TriviumVet

Nutrition is emerging as a powerful tool for preventing disease and strengthening immunity in livestock. Changemakers leading this shift explore the opportunities and hurdles that will shape evidence generation, farmer adoption, and the scaling of preventative nutrition across global production systems.

  • Evidence generation – building the data to prove measurable impact on health and productivity
  • Scaling adoption – integrating precision nutrition into commercial production systems
Panellists

Author:

Aaron Schacht

CEO
BiomEdit

Aaron Schacht

CEO
BiomEdit

Monoclonal antibodies are redefining therapeutic possibilities in animal health, offering precise, targeted alternatives to traditional treatments. With next-generation innovation expanding into new disease areas and species, changemakers at the forefront examine the opportunities and hurdles that will shape development, approval, and adoption.

  • Regulatory pathways – navigating approval processes for novel biologics
  • Clinical adoption – driving veterinary education and confidence in new therapies

Antimicrobial resistance is one of the most urgent challenges in animal and human health, demanding new approaches beyond traditional antibiotics. Changemakers developing preventative strategies and non-antibiotic alternatives explore the opportunities and hurdles that will define how these tools expand the veterinary toolkit, reduce dependence, and safeguard vital medicines.

  • Market positioning – differentiating alternatives from traditional antibiotics
  • Adoption drivers – proving cost-effectiveness and securing veterinary and farmer buy-in
Panellists

Author:

Tom Weaver

Co-Founder & Chairman
PetMedix & ArkVax

Tom Weaver

Co-Founder & Chairman
PetMedix & ArkVax

Rapid diagnostics are transforming everyday veterinary practice, enabling earlier detection and faster decision-making. Changemakers explore the latest advances in point-of-care tools, their role in improving outcomes, and the challenges of validation, adoption, and integration into workflows.

  • Validation – generating clinical evidence to support regulatory approval and vet adoption
  • Integration – embedding diagnostics into workflows for scale and commercial uptake
Moderator

Author:

Joe Harvey

Head of Animal Health
S&P Global

Joe Harvey

Head of Animal Health
S&P Global
Panellists

Author:

Richard Mellanby

Global Head of Medical Innovation and Strategy
IDEXX

Richard Mellanby

Global Head of Medical Innovation and Strategy
IDEXX